{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:08:18Z","timestamp":1777928898693,"version":"3.51.4"},"reference-count":10,"publisher":"SAGE Publications","issue":"14","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Lupus"],"published-print":{"date-parts":[[2021,12]]},"abstract":"\n Background<\/jats:title>\n Immune thrombocytopenic purpura (ITP) is an autoimmune disease, with accelerated destruction of platelets, estimated to affect 1.6\u20133.9 in 100,000 adults every year in the European Union. Glucocorticoids and intravenous immunoglobulins are common drug therapies. In refractory cases, drugs that enhance thrombopoiesis may be used. Eltrombopag is a thrombopoietin receptor agonist, known to increase platelet count in patients with refractory ITP. Thrombotic adverse events have been described in association with Eltrombopag administration.<\/jats:p>\n <\/jats:sec>\n \n Case report<\/jats:title>\n A young female patient of Ethiopian ancestry with systemic lupus erythematosus, triple Antiphospholipid (APLA) positive serology and refractory ITP who received Eltrombopag and 2\u00a0weeks later developed catastrophic APLA syndrome with severe Libman-Sacks endocarditis of the mitral and aortic valves, multiple intracerebral infracts and arterial thrombosis of the left upper limb.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Eltrombopag is a salvage drug, used in refractory ITP. Thrombotic adverse events, some of which may be life-threatening, are a possible complication, especially in high-risk patients.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/09612033211065140","type":"journal-article","created":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T03:37:49Z","timestamp":1639885069000},"page":"2304-2309","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Catastrophic anti-phospholipid syndrome with Libman-Sacks endocarditis following eltrombopag therapy for immune thrombocytopenic purpura: A case report"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5950-1684","authenticated-orcid":false,"given":"Sara","family":"Dichtwald","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Intensive Care and Pain Medicine, Meir Medical Center, KfarSaba, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avraham","family":"Meyer","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Intensive Care and Pain Medicine, Meir Medical Center, KfarSaba, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisim","family":"Ifrach","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Intensive Care and Pain Medicine, Meir Medical Center, KfarSaba, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,12,19]]},"reference":[{"key":"bibr1-09612033211065140","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01247.x"},{"key":"bibr2-09612033211065140","doi-asserted-by":"publisher","DOI":"10.2165\/11207390-000000000-00000"},{"key":"bibr3-09612033211065140","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073275"},{"key":"bibr4-09612033211065140","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0312-7"},{"key":"bibr5-09612033211065140","unstructured":"GlaxoSmithKline. PROMACTA (Eltrombopag) tablets: US prescribing information, http:\/\/www.gsksource.com\/gskprm\/htdocs\/documents\/PROMACTA-PI-MG-COMBINED.PDF (2014, accessed 26 August 2014)."},{"key":"bibr6-09612033211065140","unstructured":"Berg T, Riordan S, Karamanolis D, et al.ENABLE-ALL: safety and efficacy of Eltrombopag in thrombocytopenic hepatitis C virus-infected patients with cirrhosis who withdraw from the ENABLE-1&2 studies (abstract no.140). In: 23rd annual conference of APASL, Brisbane, Australia, 12\u201315 March 2014, 2014."},{"key":"bibr7-09612033211065140","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.10.012"},{"key":"bibr8-09612033211065140","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key119"},{"key":"bibr9-09612033211065140","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318804876"},{"key":"bibr10-09612033211065140","doi-asserted-by":"publisher","DOI":"10.1191\/0961203305lu2145rr"}],"container-title":["Lupus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033211065140","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09612033211065140","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033211065140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:24:28Z","timestamp":1777677868000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09612033211065140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":10,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1177\/09612033211065140"],"URL":"https:\/\/doi.org\/10.1177\/09612033211065140","relation":{},"ISSN":["0961-2033","1477-0962"],"issn-type":[{"value":"0961-2033","type":"print"},{"value":"1477-0962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}